A wellness program at work may make you feel good, but it won ’t improve your health
More than half of U.S. companies offer workplace wellness programs to their employees, but a new study suggests they do very little — if anything — to improve workers’ health.In an unusual clinical trial involving more than 8,000 employees of a warehouse retail chain, the presence of a wellness... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - April 19, 2019 Category: Science Authors: Leila Miller Source Type: news

Clinical Trials of ART Interruption in HIV-Infected People Clinical Trials of ART Interruption in HIV-Infected People
What have we learned from recent HIV clinical studies regarding antiretroviral treatment interruption?AIDS (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 19, 2019 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Systematic review Does periodontally accelerated osteogenic orthodontics improve orthodontic treatment outcome?
ConclusionsStudies showed significant improvements in periodontal health. Treatment duration was reduced in patients who underwent PAOO. Root resorption was not sufficiently evaluated by current literature. (Source: Dental Technology Blog)
Source: Dental Technology Blog - April 19, 2019 Category: Dentistry Source Type: news

MRI Identifies Rectal-Cancer Patients Suitable for Primary Surgery MRI Identifies Rectal-Cancer Patients Suitable for Primary Surgery
MRI criteria can be used to identify"good prognosis" rectal-cancer patients for primary surgery (without chemoradiotherapy first), according to results from the QuickSilver clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Circuit Clinical partners with Roswell Park for lung cancer clinical trials
Roswell Park patients will use Circuit Clinical's new TrialScout app to connect to clinical trial opportunities for the CIMIvax lung cancer vaccine. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 18, 2019 Category: American Health Authors: Tracey Drury Source Type: news

Vaginal Mesh Is Just One of Boston Scientific & #039;s Headaches This Year
Boston Scientific expects to take a $25 million revenue hit after FDA ordered two of its surgical mesh products off the market this week, the company disclosed in an SEC filing. Unfortunately, that's not the only revenue headwind the company has to worry about this year. Boston Scientific is one of about a handful of companies that develop paclitaxel drug-coated balloons and drug-coated stents. Paclitaxel devices received some bad press in January after a meta-analysis showed an increased risk of death for patients treated with these devices in the femoral and/or popliteal arteries of the lower limbs. Two drug-...
Source: MDDI - April 18, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Regulatory and Compliance Source Type: news

Managing a Successful Direct-to-Patient Trial Using Interactive...
Direct-to-Patient clinical trials are popular trial designs that have the potential to increase patient recruitment and retention, yet there are operational and logistical challenges to adopting these...(PRWeb April 18, 2019)Read the full story at https://www.prweb.com/releases/managing_a_successful_direct_to_patient_trial_using_interactive_response_technology_upcoming_webinar_hosted_by_xtalks/prweb16252487.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 18, 2019 Category: Pharmaceuticals Source Type: news

Bioclinica Launches NAFLD/NASH Clinical Trials Practice
Helps sponsors apply medical imaging in trials to advance development of NAFLD/NASH therapeutics.(PRWeb April 18, 2019)Read the full story at https://www.prweb.com/releases/bioclinica_launches_nafld_nash_clinical_trials_practice/prweb16252099.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 18, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves New Weight Loss Aid
BOSTON (CBS) — The FDA has approved a new weight loss aid not just for people who are obese, but people who are overweight as well. It’s called “Plenity” and it’s an oral hydrogel capsule made of cellulose and citric acid. When it enters the stomach, it releases thousands of particles that absorb water, forming small pieces of gel that increase the volume of the stomach and small intestine and make patients feel full. The manufacturer says in clinical trials, when taken before lunch and dinner, six out of 10 adults lost at least 5% of their body weight within six months. It’s designed no...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 17, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Seen On WBZ-TV Syndicated Local Dr. Mallika Marshall HealthWatch Source Type: news

Drug 'reduces' risk of kidney failure for type 2 diabetes patients
A landmark clinical trial has provided “renewed optimism” for patients with type 2 diabetes and kidney disease, after researchers found a drug reduced the risk of renal failure by almost a third. (Source: Nursing Times)
Source: Nursing Times - April 17, 2019 Category: Nursing Source Type: news

NRG Oncology awarded NCI funding for next 6 years, receives 'exceptional' score
(NRG Oncology) NRG Oncology, a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group conducting practice-changing clinical and translational research, has been awarded funding of over $95 million by the NCI for the next six years to continue its work as a lead protocol organization (LPO) program. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 17, 2019 Category: International Medicine & Public Health Source Type: news

NRG Oncology SDMC awarded NCI funding for next 6 years with 'outstanding' score
(NRG Oncology) The NRG Oncology Statistics and Data Management Center (SDMC) was notified that the center will be awarded six more years of funding from the National Cancer Institute (NCI) and will continue to serve the NCI National Clinical Trials Network (NCTN) group NRG Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 17, 2019 Category: International Medicine & Public Health Source Type: news

Oncology Clinical Trials – The Paradigm Shift of Basket Trials: Key...
In basket trials, cancers with differing histologies are pooled and the common element is a singular genetic mutation or protein alteration. The trial tests a drug that targets a common biologic...(PRWeb April 17, 2019)Read the full story at https://www.prweb.com/releases/oncology_clinical_trials_the_paradigm_shift_of_basket_trials_key_considerations_upcoming_webinar_hosted_by_xtalks/prweb16249240.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 17, 2019 Category: Pharmaceuticals Source Type: news

Quartesian LLC Executes Multi-Year Enterprise Agreement with Medrio,...
The agreement equips the CRO with a strong eClinical asset as they work to deliver top-quality services to clinical trial sponsors.(PRWeb April 17, 2019)Read the full story at https://www.prweb.com/releases/quartesian_llc_executes_multi_year_enterprise_agreement_with_medrio_securing_access_to_innovative_eclinical_functionality_and_support_services/prweb16248859.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 17, 2019 Category: Pharmaceuticals Source Type: news

Could this Peninsula company's stem cell treatment fix traumatic brain injuries?
Compared to TBI patients given a placebo, the mid-stage study's results are statistically significant — and the first to show success in a rigorous clinical trial. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 16, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

Could this Peninsula company's stem cell treatment fix traumatic brain injuries?
Compared to TBI patients given a placebo, the mid-stage study's results are statistically significant — and the first to show success in a rigorous clinical trial. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 16, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

The Kidney Cancer Association Announces $1.3 Million in New Research Opportunities
HOUSTON–April 16, 2019– The Kidney Cancer Association (KCA) is pleased to announce its Board of Directors recently approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer. The application process opens on April 17 and closes on May 20. Award winners will be announced in the Fall of 2019.“The KCA Board of Directors is committed to providing research funding with the goal of identifying new treatments and finding new ways to prevent and manage the disease,” said Christopher Wood, Board President.“With these advancements in research and a greater...
Source: Kidney Cancer Association - April 16, 2019 Category: Urology & Nephrology Source Type: news

Treatment success for diabetic kidney disease
Clinical trial findings inThe New England Journal of Medicine report that canagliflozin can reduce the risk of kidney and cardiac failure in patients with diabetes.iNews (Source: Society for Endocrinology)
Source: Society for Endocrinology - April 16, 2019 Category: Endocrinology Source Type: news

C-Path, CDISC develop therapeutic area standard to foster meaningful research for HIV
(Critical Path Institute (C-Path)) The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Therapeutic Area Standard that specifies how to structure commonly collected data and outcome measurements in clinical trials for HIV. The standard, released in the form of User Guide for data managers, statisticians, programmers and study managers, covers the areas of prevention, vaccines and treatment and is freely available on the CDISC website. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 16, 2019 Category: International Medicine & Public Health Source Type: news

Magic mouthwash effective treatment for mouth sore pain caused by radiation therapy
(Mayo Clinic) 'Magic mouthwash,' an oral rinse containing diphenhydramine, lidocaine and antacids, significantly reduced pain from oral mucositis, mouth sores, in patients receiving radiation therapy for cancers of the head and neck when compared to plaecbo. These were the findings of a multi-institution, randomized, double-blind, placebo-controlled, phase III clinical trial, led by Robert Miller, M.D., an emeritus Mayo Clinic radiation oncologist. Dr. Miller and his colleagues published their findings on Tuesday, April 16, in JAMA. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 16, 2019 Category: Cancer & Oncology Source Type: news

Magic Mouthwash effective treatment for mouth sore pain caused by radiation therapy
JACKSONVILLE, Fla. -- "Magic mouthwash," an oral rinse containing diphenhydramine, lidocaine and antacids, significantly reduced pain from oral mucositis, mouth sores, in patients receiving?radiation therapy for cancers of the head and neck when compared to placebo. These were the findings of a multi-institution, randomized, double-blind, placebo-controlled, phase III clinical trial, led by Robert Miller, M.D., [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 16, 2019 Category: Databases & Libraries Source Type: news

High mid-life resting heart rate doubles risk of early death
And rising heart rate during 50s is linked to increased risk of heart disease Related items fromOnMedica Follow clinical guidance to measure BP in both arms Too few women take part in many CVD clinical trials Cycling and treadmill workstations better for health Heart attack protocol eliminates gender gap in outcome Polypill could halve cardiovascular events (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 16, 2019 Category: UK Health Source Type: news

Glaukos touts 5-year study of glaucoma stents
This study shows that not only are Glaukos’ iStents as effective as once-daily topical travoprost in controlling IOP, but they also succeed at maintaining IOP reductions over the long-term with fewer additional medications.” Three-year outcomes of this study were published in 2016 in Ophthalmology and Therapy. The most recent article detailing five-year outcomes may be accessed online here. “This latest publication represents the first-ever five-year, protocol-driven, randomized evaluation of standalone iStent implantation in newly diagnosed glaucoma patients,” said Glaukos prez & CEO Thomas Bur...
Source: Mass Device - April 15, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Clinical Trials Featured Implants News Well Optical/Ophthalmic Vision Glaukos Ivantis Source Type: news

Tackling Precision Medicine with a New Kind of Decision Support
When Clynt Taylor joined Intervention Insights two years ago as CEO, the Burlington, MA-based company had already developed a platform that was being used to inform the results of molecular tests in oncology. At that time the platform was designed to take results from a molecular test and supplement that information with levels of evidence to help doctors determine which available treatment option had the highest level of evidence to support it. It was a good idea, Taylor says, but when the company started in 2011 the need for that service was greater than it is today. It wasn't long before Taylor recognized that the real ...
Source: MDDI - April 15, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Digital Health Source Type: news

Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's
The South San Francisco company is putting its IPO where its mouth is — hoping to take its lead drug, targeting a tooth-loss-causing bacteria that migrates from the mouth to the brain, into a Phase II/III clinical trial soon. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 15, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Patch Offers a New Approach for Treating Iron Deficiency
Patch-like wearables are becoming increasingly popular in medtech. The latest device to employ such a design and make medtech headlines is transdermal patch being developed by Fe3 Medical. San Antonio, TX-based Fe3 said its biphasic iontophoretic transdermal technology is for the treatment of iron deficiency anemia. The firm announced results from its first human study of the patch-like device. The human study focused on the safety and tolerability of Fe3's iontophoretic transdermal technology designed to bypass ionic resistance build up in the skin. The human study follows a series of successful preclinical studies demons...
Source: MDDI - April 15, 2019 Category: Medical Devices Authors: Omar Ford Tags: Adhesives Source Type: news

Cancer-Related Insomnia: New Research Finds Effective Treatments
This study was a first of its kind. It involved a head-to-head comparison of acupuncture and cognitive behavioral therapy, enrolled patients with many different types of cancer and included nearly 30% minority participants. Previous studies focused solely on breast cancer and included 90% white participants. Limitations of the previous research make it difficult to determine if the results are applicable to patients with other cancers and people of diverse backgrounds. Cognitive Behavioral Therapy and Acupuncture Are Effective Acupuncture and cognitive behavioral therapy treatments produced clinically meaningful reduction...
Source: Asbestos and Mesothelioma News - April 15, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Exclusive: Philadelphia startup breaks new ground against cancer that killed John McCain
The company, founded by Jefferson researchers, posted positive clinical trial data from an early study testing its immunotherapy vaccine in patients with glioblastoma. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 15, 2019 Category: American Health Authors: John George Source Type: news

PureTech Health-affiliated weight loss drug gets FDA approval
Nearly two decades after being founded, life sciences company-creator and incubator PureTech Health has helped bring its first product to market. PureTech-affiliate Gelesis last week received FDA approval for a weight-loss capsule that releases a special formatted gel that fills up a portion of a person's stomach. Overweight subjects who took the prescription drug, Plenity, before eating were almost twice as likely to meet a weight loss goa l, according to clinical trial data. Plenity is the first… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 15, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

High-dose vitamin D shows benefit in patients with advanced colorectal cancer
Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by delaying progression of the disease, say scientists from Dana-Farber Cancer Institute. Prompted by the "very encouraging" results of the SUNSHINE clinical trial, the potential benefits of vitamin D supplementation in metastatic colorectal cancer will (Source: World Pharma News)
Source: World Pharma News - April 15, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Statins safe for preventing cardiovascular events in rheumatoid arthritis patients
(Wiley) Results from a large clinical trial indicate that patients with rheumatoid arthritis are likely to experience the same level of cardiovascular benefits from statins as other individuals, without additional risks. The findings appear in Arthritis& Rheumatology, an official journal of the American College of Rheumatology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2019 Category: International Medicine & Public Health Source Type: news

Drug reduces risk of kidney failure in people with diabetes, study finds
(Stanford Medicine) A new landmark clinical trial shows that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2019 Category: International Medicine & Public Health Source Type: news

Late breaking clinical trial data at ISN World Congress of Nephrology
(Tania Ewing and Associates) TO BE LIVE STREAMED - Three internationally significant presentations at the World Congress of Nephrology today (April 15, 2019) will reveal new and highly relevant clinical data that may alter the treatment of kidney disease globally. The sessions (from 8:30 to 10:30 AEST time, Melbourne) will be live streamed by the International Society of Nephrology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 14, 2019 Category: International Medicine & Public Health Source Type: news

Gene-silencing: 'New class' of medicine reverses disease porphyria
Gene silencing drugs spared patients from the crippling pain caused by porphyria, in a clinical trial. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 13, 2019 Category: Consumer Health News Source Type: news

European researchers, pharma players team up on gait detecting sensor
The European Federation of Pharmaceutical Industries and Associations and researchers across Europe teamed up on a €50 million project to develop a wearable sensor of clinical trials.  (Source: mobihealthnews)
Source: mobihealthnews - April 12, 2019 Category: Information Technology Source Type: news

Mallinckrodt Completes Full Enrollment of its Phase 3 Clinical Trial for StrataGraft(R) Regenerative Skin Tissue
Pivotal Phase 3 study is evaluating efficacy and safety of investigational regenerative skin tissue in adults with deep partial-thickness burns STAINES-UPON-THAMES, United Kingdom, April 12, 2019 -- (Healthcare Sales & Marketing Network) -- Mallinckrod... Devices, Regenerative Medicine, Wound Care Mallinckrodt, StrataGraft, regenerative skin tissue (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 12, 2019 Category: Pharmaceuticals Source Type: news

Novo Nordisk and Gilead team up to test fatty liver disease treatment
Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH. (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Novo Biosciences achieves major milestones in moving trodusquemine into clinical trials
(Novo Biosciences) Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy (DMD). Trodusquemine is a repurposed drug candidate that has already been shown to be well tolerated by patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2019 Category: International Medicine & Public Health Source Type: news

Stem Cell trial for osteoarthritis patients reduces pain, improves quality of life
(University Health Network) In the first North American stem cell clinical trial for osteoarthritis of the knee patients, 12 patients were given injections of their own stem cells and followed for 12 months. The results show a significant improvement in pain levels and quality of life. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2019 Category: International Medicine & Public Health Source Type: news

RV Pacing May Worsen Even Preserved-EF Heart Failure RV Pacing May Worsen Even Preserved-EF Heart Failure
A randomized clinical trial is needed, experts say, to determine whether CRT should be preferred in this setting, as is the case for reduced-EF heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 11, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Alpha Tau receives ISO certification
Israeli radiation therapy technology developer Alpha Tau Medical said it has...Read more on AuntMinnie.comRelated Reading: Alpha Tau prepares clinical trials for Alpha DaRT (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 11, 2019 Category: Radiology Source Type: news

Clinical trial firm with Oregon site fills out executive team
Just months after Durham's newest clinical research organization launched, the company is rounding out its executive team, bringing industry executives into their nationally expanding company. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 11, 2019 Category: Health Management Authors: Seth Thomas Gulledge Source Type: news

Second Sight Medical releases early feasibility data on Orion cortical implant
Second Sight Medical (NSDQ:EYES) today announced preliminary results from a small feasibility study of its Orion cortical implant, which is designed to give eyesight to the blind. Sylmar, Calif.-based Second Sight’s Orion is designed to connect the camera in a pair of eyeglasses with an implant that receives the camera signal and translates it to the visual cortex in the brain, bypassing the eye and the optic nerve entirely. The company’s Argus II device, which uses a retinal implant to receive the camera’s signal, is already on the U.S. market. Interim data from a five-year early feasibility study, prese...
Source: Mass Device - April 11, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Featured Optical/Ophthalmic Second Sight Source Type: news

CAR T-Cell Therapy for Mesothelioma Proving Effective in Clinical Trial
Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center believes novel CAR T-cell therapy will be part of future, standard-of-care treatment for malignant pleural mesothelioma. The therapy involves the laboratory reprograming of a patient’s T cells — a type of white blood cell — to attack the cancer by targeting mesothelin, a surface protein. CAR T-cell therapy is a form of immunotherapy that could extend mesothelioma survival significantly. “That’s my goal. That’s what we’ve been working toward for many years,” Adusumilli told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - April 11, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Intrinsic Therapeutics raises $52m for Barricaid annulus seal
Intrinsic Therapeutics said today that it raised $52 million in a new round of equity financing to support the U.S. commercialization of its Barricaid annulus seal. The Boston-based company’s Barricaid implant is a polymeric mesh that is designed to sit at the posterior intervertebral disc space and is connected to a metal anchor that is attached to the vertebral body. The device is intended as an adjunct for lumbar limited discectomy to replace missing or damaged parts of the annulus to prevent re-herniation, disc collapse, the return of sciatica and potentially to help stave off low back pain. Intrinsic Therapeutic...
Source: Mass Device - April 11, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Spinal Wall Street Beat Intrinsic Therapeutics Source Type: news

Speed Clinical Trials from Start to Close: The Path to a Modern CTMS,...
The rising volume and global distribution of clinical studies have made today’s trials more complex. To achieve better study analytics and greater trial efficiency, sponsors can adopt cloud-based...(PRWeb April 11, 2019)Read the full story at https://www.prweb.com/releases/speed_clinical_trials_from_start_to_close_the_path_to_a_modern_ctms_upcoming_webinar_hosted_by_xtalks/prweb16236234.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 11, 2019 Category: Pharmaceuticals Source Type: news

TAVR Puts the Swagger Back in Mick Jagger
Rolling Stones frontman Mick Jagger’s recent surgery is putting a huge spotlight on the transcatheter aortic valve replacement (TAVR) market. Late last week, Jagger tweeted that his procedure was a success and thanked fans for their support.   Thank you everyone for all your messages of support, I’m feeling much better now and on the mend - and also a huge thank you to all the hospital staff for doing a superb job. — Mick Jagger (@MickJagger) April 5, 2019 Problems for the 75-year-old began late last month after the rocker fell ill. As a result, the Rolling...
Source: MDDI - April 10, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news

Three-parent baby born in first ever clinical trial to test the technique
The 32-year-old Greek woman had four failed IVF attempts before she heard about the trial by Spanish doctors. On Tuesday, she gave birth to a 6.5-pound boy, and both mother and baby are in good health. (Source: the Mail online | Health)
Source: the Mail online | Health - April 10, 2019 Category: Consumer Health News Source Type: news

Angel Medical ’ s Guardian implantable heart monitor fails on efficacy endpoint
A clinical trial of the Guardian implantable heart attack monitor made by Angel Medical Systems failed to meet its efficacy endpoint, but suggested that the device could be used to help detect “silent” heart attacks. Wilmington, Del.-based AngelMed won FDA clearance a year ago for the Guardian device for patients with prior acute coronary syndrome events including myocardial infarctions or unstable angina at high risk for further ACS events. Its 907-patient Alerts study randomized patients implanted with Guardian to either six months with the alert function active for the treatment group or six months with...
Source: Mass Device - April 10, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Featured Angel Medical Systems Inc. Source Type: news

Conformal Medical launches LAA seal study
Conformal Medical said yesterday that it launched an investigational device exemption trial for a device designed to seal off the heart’s left atrial appendage to help prevent stroke in atrial fibrillation patients. Nashua, N.H.-based Conformal’s device is designed to adapt to the each patient’s individual physiology, to be easier to implant with less imaging and without general anesthesia. The 45-patient, single-arm study is designed to evaluate the device’s performance, with an estimated primary completion date of April 2020 and a final completion date of June 2025, according to ClinicalTrials.gov...
Source: Mass Device - April 10, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Implants Clinical Trials Featured Conformal Medical Source Type: news